Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Harbour Bio Starts China Phase III Trial of Novel Dry Eye Treatment

publication date: Mar 15, 2021

Harbour BioMed has dosed the first patient in the China arm of a global Phase III trial of a novel treatment for moderate-to-severe dry eye disease (DED). Tanfanercept (HBM9036) is a tumor necrosis factor (TNF) receptor-1 fragment-based anti-inflammatory biologic. In 2017, Harbour in-licensed greater China rights to Tanfanercept from South Korea's HanAll Biopharma (KS: 009420) in a two-drug $81 million agreement. The other candidate in the HanAll agreement is an IgG-mediated molecule also aimed at autoimmune diseases. Harbour is a US-Netherlands-Shanghai biopharma. More details....

Stock Symbol: (HK: 02142)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.